title: Growth hormone-releasing peptides and the cardiovascular system.
abstract: Growth Hormone (GH)-releasing peptides (GHRPs) and their non peptidyl analogues are synthetic molecules which exhibit strong, dosedependent and reproducible GH-releasing activity but also significant PRL- and ACTH/cortisol-releasing effects. An influence of these compounds on food intake and sleep pattern has been also shown. The neuroendocrine activities of GHRPs are mediated by specific receptors subtypes that have been identified in the pituitary gland, hypothalamus and various extra-hypothalamic brain regions with (125)I-Tyr-Ala-hexarelin, an octapeptide of the GHRP family. In addition, GHRP receptors were also present in different peripheral tissues such as heart, adrenal, ovary, testis, lung and skeletal muscle, with a density significantly higher than that found in the hypothalamo-pituitary -system. A remarkable specific (125)I-Tyr-Ala-hexarelin binding was observed in the human cardiovascular system where the highest binding levels were detected in ventricles, followed by atria, aorta, coronaries, carotid, endocardium and vena cava. The binding of the radioligand to cardiac membranes was inhibited by unlabeled Tyr Ala hexare lin and hexarelin as well as by GHRP-6, GHRP-1 and GHRP-2 but not by MK-677, a non peptidyl GHRP analog. In other experiments on H9c2 myocytes, a fetal cardiomyocytes-derived cell line, specific GHRP binding was found and hexarelin showed an anti-apoptotic activity. On the other hand, in vivo studies in animals and in humans showed that GHRPs possess direct cardiotropic actions. In fact, hexarelin protects from ischemia-induced myocardial damage in aged and GH deficient rats while hexarelin shows a positive inotropic effect in normal subjects as well as in patients with GH deficiency. In conclusion, GHRPs possess extra--neuroendocrine biological activity and, particularly, show direct GH-independent cardiotropic effects.
authors.affiliation: Departments of Pharmacology, Via P. Giuria, 13, 10125 Turin, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Muccioli
authors.forename: F
authors.initials: F
authors.lastname: Broglio
authors.forename: M R
authors.initials: MR
authors.lastname: Valetto
authors.forename: C
authors.initials: C
authors.lastname: Ghè
authors.forename: F
authors.initials: F
authors.lastname: Catapano
authors.forename: A
authors.initials: A
authors.lastname: Graziani
authors.forename: M
authors.initials: M
authors.lastname: Papotti
authors.forename: G
authors.initials: G
authors.lastname: Bisi
authors.forename: R
authors.initials: R
authors.lastname: Deghenghi
authors.forename: E
authors.initials: E
authors.lastname: Ghigo
mesh_terms: D000818:Animals; D002320:Cardiovascular Physiological Phenomena; D002319:Cardiovascular System / Q000187:drug effects*; D005260:Female; D013007:Growth Hormone-Releasing Hormone; D006728:Hormones / Q000494:pharmacology*; D019382:Human Growth Hormone / Q000378:metabolism; D006801:Humans; D008297:Male; D009842:Oligopeptides / Q000494:pharmacology; D018013:Receptors, Neuropeptide / Q000502:physiology; D018017:Receptors, Pituitary Hormone-Regulating Hormone / Q000502:physiology
chemical_list: D006728:Hormones; D009842:Oligopeptides; D018013:Receptors, Neuropeptide; D018017:Receptors, Pituitary Hormone-Regulating Hormone; C086184:hexarelin; D019382:Human Growth Hormone; D013007:Growth Hormone-Releasing Hormone; C048250:somatotropin releasing hormone receptor